Erasca, Inc.
Financials
Valuation Metrics
Erasca, Inc.'s Market Cap is $4.91B. At end of 2025 it was $1.05B. Ranked #1311 of 3,115 in US market (top 42%), #443 of 1,472 on NASDAQ (top 30%), #75 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.91B | US#1,311/3,115 Sec#75/265 |
| Revenue | $0.00 | US#2,861/3,115 Sec#193/265 |
| Net Income | $-287M | US—/3,115 Sec—/265 |
| Total Assets | $435M | US#2,813/3,115 Sec#175/265 |
| Net Assets | $362M | US#2,428/3,115 Sec#144/265 |
| Employees | 103 | US#2,609/3,115 Sec#175/265 |
| Value | ||
| P/B | 13.57x | US#2,723/3,115 Sec#205/265 |
| FCF Yield | -2.00% | US—/3,115 Sec—/265 |
| Profitability | ||
| ROE | -79.37% | US#2,762/3,115 Sec#194/265 |
| ROA | -66.02% | US#3,022/3,115 Sec#235/265 |
| Financial Health | ||
| Debt Ratio | 20.22% | US#227/3,115 Sec#77/265 |
| Total Debt | $45M | US#2,631/3,115 Sec#157/265 |
| FCF | $-98M | US#2,631/3,115 Sec#144/265 |
| Cash | $43M | US#2,642/3,115 Sec#233/265 |
| Current Ratio | 8.29x | US#306/3,115 Sec#94/265 |
| Performance | ||
| 1Y Return | 479.96% | US#5/3,115 Sec#2/265 |
| 1M Return | -4.78% | US#932/3,115 Sec#52/265 |
| From 52W High | -42.20% | US#2,281/3,115 Sec#151/265 |
| 1Y MDD | -59.46% | US#2,710/3,115 Sec#203/265 |
| Trading | ||
| Volume | 3,749,210 shares | US#254/3,115 Sec#17/265 |
| Trading Value | $54M | US#837/3,115 Sec#50/265 |
| Per Share | ||
| EPS | $-0.82 | US—/3,115 Sec—/265 |
| BPS | $1.03 | US#2,690/3,115 Sec#202/265 |
Company Info
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.